Standout Papers

Updated safety results from phase 3 lecanemab study in early... 2022 2026 2023 20242.4k
  1. Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease (2024)
    Lawrence S. Honig, Marwan N. Sabbagh et al. Alzheimer s Research & Therapy
  2. Lecanemab in Early Alzheimer’s Disease (2022)
    Christopher H. van Dyck, Chad J. Swanson et al. New England Journal of Medicine

Immediate Impact

10 by Nobel laureates 11 from Science/Nature 51 standout
Sub-graph 1 of 22

Citing Papers

Ultrasound Blood–Brain Barrier Opening and Aducanumab in Alzheimer’s Disease
2024 Standout
Early onset diagnosis in Alzheimer’s disease patients via amyloid-β oligomers-sensing probe in cerebrospinal fluid
2024 Standout

Works of Michelle Gee being referenced

Lecanemab in Early Alzheimer’s Disease
2022 Standout

Author Peers

Author Last Decade Papers Cites
Michelle Gee 1237 1596 522 718 24 3.4k
Kimberly Schafer 1488 1843 934 623 38 4.6k
Gopalan Sethuraman 988 1863 597 656 60 3.7k
Ara S. Khachaturian 1347 1704 813 696 47 4.1k
Vitaliy Ovod 1411 2886 369 914 25 4.1k
H. Michael Arrighi 1863 2038 562 1005 51 6.1k
Tom Kasten 592 2188 342 835 19 3.3k
Lutz Froelich 1273 1735 535 726 51 3.6k
Lynn D. Kramer 1919 2248 733 874 60 4.5k
Michio Kanekiyo 1007 1683 505 661 26 2.9k
Shobha Dhadda 1493 2392 1060 838 66 4.9k

All Works

Loading papers...

Rankless by CCL
2026